Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.

  title={Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas.},
  author={Viviane Folny and Danielle Raufaste and Ludovit Lukovic̆ and Brigitte Pouzet and Pierrick Rochard and Marc Pascal and Claudine Serradeil‐Le Gal},
  journal={American journal of physiology. Endocrinology and metabolism},
  volume={285 3},
Vasopressin (AVP) receptors present in In-R1-G9 cells, a hamster glucagon-secreting alpha-pancreatic cell line, were characterized using SSR-149415, a selective nonpeptide V1b receptor antagonist, and reference AVP compounds. Binding experiments, using [3H]AVP as a ligand, identified a single population of high-affinity binding sites. SSR-149415 competitively inhibited this binding and exhibited nanomolar and stereospecific affinity for these sites. The affinity of various AVP/oxytocin ligands… 

Figures and Tables from this paper

The Discovery of Novel Vasopressin V1b Receptor Ligands for Pharmacological, Functional and Structural Investigations

This work designed synthetic peptides derived from [deaminocysteine1,arginine8]vasopressin (dAVP), modified in position 4 by various amino acid residues, which have a high affinity and an excellent selectivity for the human V1b receptor subtype.

An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders.

SSR149415 is a new dual anxiolytic/antidepressant compound, which appears to be free of the known side effects of classical anxioleytic/antsidepressant drugs.

Biological characterization of rodent and human vasopressin V1b receptors using SSR-149415, a nonpeptide V1b receptor ligand.

SSR-149415/[(3)H] SSR- 149415 are unique tools for studying animal and human V(1b)R from native or recombinant origin and show intense specific labeling confined to corticotroph cells and absence of labeling in the other tissues examined.

Vasopressin stimulates insulin release from islet cells through V1b receptors: a combined pharmacological/knockout approach.

It is shown that vasopressin-stimulated insulin release from islet cells is mediated via V1b receptors, and the AVP effect on insulin release was entirely lost in mice lacking the V1a receptor but was preserved in mice lacked the V 1a receptor.

Mutual regulation of vasopressin- and oxytocin-induced glucagon secretion in V1b vasopressin receptor knockout mice.

Results demonstrate that V1b receptors can mediate OT-induced glucagon secretion and OT receptors can Mediate AVP-induced glucose secretion in islets from V 1bR+/+mice in the presence of a heterologous antagonist, while AVP and OT can stimulate glucagon secretions through the OT receptors in V1BR-/-mice, suggesting that the other receptor can compensate when one receptor is absent.

CNS Drug Reviews

The anxiolytic effects of SSR149415 have been demonstrated in various Generalized Anxiety Disorders (GAD) models and it is as effective as the benzodiazepine diazepam in the acute stress exposure test.

The vasopressin Avprlb receptor: Molecular and pharmacological studies

The Avpr1b KO also appears to be an excellent model to study the contribution of the AvPR1b in the HPA axis response to acute and perhaps some chronic (repeated) stressors where corticotrophin-releasing hormone and other genes involved in theHPAaxis response to stress do not appear to compensate for the loss of theAvpr1B.

Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.

Recently, we synthesized and characterized the first selective V(1b) vasopressin (VP)/oxytocin receptor agonist, d[Cha(4)]arginine vasopressin. However, this agonist was only selective for the human

Conivaptan: A Dual Receptor Vasopressin V1a/V2 Antagonist

Conivaptan has been shown to correct hyponatremia in euvolemic or hypervolemic patients and its efficacy and safety for short-term use have led to the Food and Drug Administration approval of its intravenous form.

Molecular pharmacology of human vasopressin receptors.

None of the 22 AVP/OT analogs tested has a better affinity for the human V3R than AVP itself, and several peptide antagonists do not select well between V1R and OTR, underscoring the need for developing specific and potent analogs interacting specifically with a given human A VP/OT receptor subtype.

Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.

SR 121463A is the most potent and selective, orally active V2 antagonist yet described and could be a powerful tool for exploring V2 receptors and the therapeutical usefulness of V2 blocker aquaretic agents in water-retaining diseases.

Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.

Characterization of human vascular V1a receptors showed that [125I]-linear AVP antagonist binding to human VSMC membranes was time dependent, reversible, and saturable, and strongly suggested the existence of human AVP V 1a-receptor subtypes.

1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.

Extrapituitary expression of the rat V1b vasopressin receptor gene.

RNA blot analysis, reverse transcription PCR, and in situ hybridization studies reveal that V1b receptor mRNA is expressed in the majority of pituitary corticotropes as well as in multiple brain regions and a number of peripheral tissues, including kidney, thymus, heart, lung, spleen, uterus, and breast.

Characterization of receptors mediating AVP- and OT-induced glucagon release from the rat pancreas.

It is concluded that AVP and OT increase glucagon release under the physiological condition through the activation of V1b and OT receptors, respectively.

Biochemical and Pharmacological Properties of SR 49059 , a New , Potent , Nonpeptide Antagonist of Rat and Human Vasopressin Via Receptors

SR 49059 is the most potent and selective nonpeptide AVP V la antagonist described so far, with marked affinity, selectivity, and efficacy toward both animal and human receptors.

Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor.

Cloning and characterization of the human V3 pituitary vasopressin receptor